NASDAQ:GLUE Monte Rosa Therapeutics Q1 2024 Earnings Report $19.35 -0.22 (-1.12%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$19.89 +0.54 (+2.79%) As of 06:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Monte Rosa Therapeutics EPS ResultsActual EPS-$0.53Consensus EPS -$0.56Beat/MissBeat by +$0.03One Year Ago EPSN/AMonte Rosa Therapeutics Revenue ResultsActual Revenue$1.06 millionExpected Revenue$4.29 millionBeat/MissMissed by -$3.23 millionYoY Revenue GrowthN/AMonte Rosa Therapeutics Announcement DetailsQuarterQ1 2024Date5/9/2024TimeN/AConference Call DateThursday, May 9, 2024Conference Call Time7:00AM ETUpcoming EarningsMonte Rosa Therapeutics' Q1 2026 earnings is estimated for Thursday, May 7, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Monte Rosa Therapeutics Earnings HeadlinesMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 5 at 4:01 PM | globenewswire.comMonte Rosa Therapeutics, Inc. (GLUE) Presents at AACR Annual Meeting 2026 - SlideshowApril 23, 2026 | seekingalpha.comRevealed: The World’s First Trillion-Dollar RobotJensen Huang stood in Las Vegas and laid out Nvidia's vision for building the world's first trillion-dollar robot. But there's one thing Nvidia can't do alone. A virtually unknown $7 company holds the technology Nvidia needs to make that vision a reality. Analyst Michael Robinson - who called Nvidia at $0.80 and Bitcoin at $300 - has identified this stock as his next potential winner, with nearly 20 prior calls returning 1,000% or more.May 6 at 1:00 AM | Weiss Ratings (Ad)Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital RaiseApril 21, 2026 | fool.comMonte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed ...April 20, 2026 | markets.businessinsider.comMonte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid TumorsApril 20, 2026 | globenewswire.comSee More Monte Rosa Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Monte Rosa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monte Rosa Therapeutics and other key companies, straight to your email. Email Address About Monte Rosa TherapeuticsMonte Rosa Therapeutics (NASDAQ:GLUE) is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden. The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience. In immuno-oncology, Monte Rosa applies its platform to better understand tumor microenvironments and to design molecules that modulate immune cell activity. In neuroscience, the company focuses on identifying targets implicated in neurodegenerative and neuroinflammatory disorders. Through this dual therapeutic focus, Monte Rosa seeks to advance candidates from early discovery through lead optimization and into partnerships or further development stages. Monte Rosa operates at the intersection of technology and biology, collaborating with academic institutions and industry partners to validate its discoveries and expand its library of therapeutic assets. The company is led by a team of experienced executives and scientists with backgrounds in genomics, AI, drug development and venture financing. While primarily based in the United States, Monte Rosa’s platform and partnerships enable it to engage with global research networks and to pursue programs with worldwide impact.View Monte Rosa Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)argenex (5/7/2026)Datadog (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026)W.W. Grainger (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
